TREXIMET

Serial Number 77230134
Registration 3493620
800

Registration Progress

Application Filed
Jul 16, 2007
Under Examination
Feb 26, 2008
Approved for Publication
Nov 14, 2007
Published for Opposition
Dec 4, 2007
Registered
Aug 26, 2008

Trademark Image

TREXIMET

Basic Information

Serial Number
77230134
Registration Number
3493620
Filing Date
July 16, 2007
Registration Date
August 26, 2008
Published for Opposition
December 4, 2007
Renewal Date
August 26, 2018
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
800
Status Date
Oct 2, 2017
Registration
Registered
Classes
005

Rights Holder

CURRAX PHARMACEUTICALS LLC

16
Address
155 Franklin Road, Suite 450
Brentwood, TN 37027

Ownership History

Glaxo Group Limited

Original Applicant
03
Greenford, Middlesex GB

Glaxo Group Limited

Owner at Publication
03
Greenford, Middlesex GB

Glaxo Group Limited

Original Registrant
03
Brentford, Middlesex GB

WORRIGAN LIMITED

New Owner After Registration #1
99
DUBLIN 4 IE

PERNIX IRELAND LIMITED

New Owner After Registration #2
16
DUBLIN 4 IE

CURRAX PHARMACEUTICALS LLC

New Owner After Registration #3
16
Brentwood, TN

Legal Representation

Attorney
Andrew N. Spivak

USPTO Deadlines

Next Deadline
1141 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2008-08-26)
Due Date
August 26, 2028
Grace Period Ends
February 26, 2029

Application History

44 events
Date Code Type Description
Jul 27, 2021 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 27, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 27, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 27, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 27, 2021 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 8, 2019 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Oct 2, 2017 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 2, 2017 89AG O REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Oct 2, 2017 RNL1 Q REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Oct 2, 2017 NA89 E NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Aug 28, 2017 E89R I TEAS SECTION 8 & 9 RECEIVED
Aug 26, 2017 REM2 E COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Nov 30, 2016 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 30, 2016 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 22, 2015 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 27, 2014 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 28, 2014 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 28, 2014 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
May 28, 2014 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
May 6, 2014 E815 I TEAS SECTION 8 & 15 RECEIVED
May 6, 2014 815F I REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
Mar 25, 2013 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 25, 2013 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 12, 2010 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 29, 2009 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 29, 2009 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 26, 2008 R.PR A REGISTERED-PRINCIPAL REGISTER
Jul 23, 2008 REGV O LAW OFFICE REGISTRATION REVIEW COMPLETED
Jul 20, 2008 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jun 27, 2008 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Jun 24, 2008 EISU I TEAS STATEMENT OF USE RECEIVED
Jun 24, 2008 IUAF S USE AMENDMENT FILED
Jun 18, 2008 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 18, 2008 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 18, 2008 EXT1 S SOU EXTENSION 1 FILED
Jun 18, 2008 EX1G S SOU EXTENSION 1 GRANTED
Feb 26, 2008 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT
Dec 4, 2007 PUBO A PUBLISHED FOR OPPOSITION
Nov 14, 2007 NPUB O NOTICE OF PUBLICATION
Oct 31, 2007 ALIE A ASSIGNED TO LIE
Oct 31, 2007 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 29, 2007 DOCK D ASSIGNED TO EXAMINER
Sep 29, 2007 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 20, 2007 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment and/or alleviation of diseases of the central nervous system, including migraines, which are distributed by prescription only
First Use Anywhere: Apr 28, 2008
First Use in Commerce: Apr 28, 2008

Classification

International Classes
005